Ovid Therapeutics Inc
NASDAQ:OVID
Ovid Therapeutics Inc
Cash from Financing Activities
Ovid Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ovid Therapeutics Inc
NASDAQ:OVID
|
Cash from Financing Activities
$30.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
152%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Ovid Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
30.5m
USD
Based on the financial report for Dec 31, 2023, Ovid Therapeutics Inc's Cash from Financing Activities amounts to 30.5m USD.
What is Ovid Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
152%
Over the last year, the Cash from Financing Activities growth was 15 168%. The average annual Cash from Financing Activities growth rates for Ovid Therapeutics Inc have been -13% over the past three years , 152% over the past five years .